Clinical trials: Moderate Asthma
Asthma
Single and Multiple Ascending Dose Study of TD-8236 by Inhalation
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 3 parts: Part A is a single ascending dose (SAD) study in healthy subjects, Part B is a multiple ascending dose (MAD) study in…
- Trial name
- NCT03652038
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Asthma
A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
Asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory conditions involving the small airways with airflow limitations resulting from genetic and environmental interactions.
- Trial name
- NCT03344406
- Testing
- Telephonic interviews, E-RS: COPD, Supplemental asthma items
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma
Adults With Moderate to Severe Asthma
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above.
- Trial name
- NCT00642122
- Testing
- Budesonide
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks.
- Trial name
- NCT00442351
- Testing
- Asmanex twisthaler
- Volunteers
- 26 people
- Sponsor
- Organon and Co
Asthma
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to…
- Trial name
- NCT01568762
- Testing
- VAK694, QAX576
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Mild or Moderate Asthma
Gemini Symbicort pMDI
The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.
- Trial name
- NCT00646516
- Testing
- budesonide/formoterol (Symbicort)
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Asthma
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.
- Trial name
- NCT00830102
- Testing
- fluticasone propionate, formoterol fumarate
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 64 people
- Sponsor
- SkyePharma AG
Moderate to Severe Persistent Asthma
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
- Trial name
- NCT04773678
- Testing
- CBP-201
- Where
- 76 sites in United States, China and 3 more
- Volunteers
- 322 people
- Sponsor
- Connect Biopharm LLC
Asthma
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
- Trial name
- NCT00044824
- Testing
- Fexofenadine
- Where
- 7 sites in United States, Costa Rica and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Asthma
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days.
- Trial name
- NCT00549744
- Testing
- GSK256066
- Where
- 3 sites in New Zealand, South Africa
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice…
- Trial name
- NCT00449501
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 46 sites in United States
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Healthy Participants, Asthma
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants…
- Trial name
- NCT06213844
- Testing
- IBI3002
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Asthma
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00219323
- Testing
- Omalizumab
- Where
- Japan
- Volunteers
- 133 people
- Sponsor
- Novartis
Asthma
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler.
- Trial name
- NCT00649025
- Testing
- FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
- Where
- 103 sites in United States, Argentina and 8 more
- Volunteers
- 438 people
- Sponsor
- SkyePharma AG
Asthma
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
- Trial name
- NCT04203797
- Testing
- dupilumab
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals